ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
CNY 8.76
(1.04%)
CNY 8.76
(1.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 127.06 Million CNY | 73.5% |
| 2022 | 25.13 Million CNY | -15.23% |
| 2021 | 40.52 Million CNY | 210.16% |
| 2020 | -177.15 Million CNY | -175.01% |
| 2019 | 57.72 Million CNY | -17.45% |
| 2018 | 88.93 Million CNY | 25.54% |
| 2017 | 112.54 Million CNY | -19.12% |
| 2016 | 108.5 Million CNY | 23.53% |
| 2015 | 90.26 Million CNY | -1.51% |
| 2014 | 104.27 Million CNY | 34.92% |
| 2013 | 72.41 Million CNY | 9.94% |
| 2012 | 67.42 Million CNY | 13.72% |
| 2011 | 61.14 Million CNY | -15.61% |
| 2010 | 69.47 Million CNY | 34.96% |
| 2009 | 56.48 Million CNY | 62.32% |
| 2008 | 27.76 Million CNY | 69.14% |
| 2007 | 20.57 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 26.94 Million CNY | 5.55% |
| 2024 Q1 | 28.41 Million CNY | -15.19% |
| 2024 Q2 | 25.52 Million CNY | -42.79% |
| 2023 Q4 | 45.13 Million CNY | 109.05% |
| 2023 FY | - CNY | 73.5% |
| 2023 Q2 | -8.21 Million CNY | -147.11% |
| 2023 Q3 | 21.59 Million CNY | 362.86% |
| 2023 Q1 | 17.43 Million CNY | 195.98% |
| 2022 Q1 | 15.48 Million CNY | 162.1% |
| 2022 Q4 | -18.16 Million CNY | -229.05% |
| 2022 FY | - CNY | -15.23% |
| 2022 Q3 | 14.07 Million CNY | 962.17% |
| 2022 Q2 | 1.32 Million CNY | -91.44% |
| 2021 FY | - CNY | 210.16% |
| 2021 Q1 | 16.36 Million CNY | 125.6% |
| 2021 Q2 | 11.61 Million CNY | -29.04% |
| 2021 Q3 | 21.47 Million CNY | 84.94% |
| 2021 Q4 | -24.94 Million CNY | -216.14% |
| 2020 Q4 | -63.92 Million CNY | -67.73% |
| 2020 FY | - CNY | -175.01% |
| 2020 Q1 | -30.26 Million CNY | -167.92% |
| 2020 Q2 | -15.59 Million CNY | 48.46% |
| 2020 Q3 | -38.11 Million CNY | -144.38% |
| 2019 FY | - CNY | -17.45% |
| 2019 Q4 | -11.29 Million CNY | -318.27% |
| 2019 Q3 | 5.17 Million CNY | -83.87% |
| 2019 Q2 | 32.08 Million CNY | -1.1% |
| 2019 Q1 | 32.43 Million CNY | -3.13% |
| 2018 Q4 | 33.48 Million CNY | 172.69% |
| 2018 Q3 | 12.27 Million CNY | -46.89% |
| 2018 FY | - CNY | 25.54% |
| 2018 Q1 | 9.32 Million CNY | 147.08% |
| 2018 Q2 | 23.12 Million CNY | 147.96% |
| 2017 Q3 | 11.34 Million CNY | -53.94% |
| 2017 Q4 | 3.77 Million CNY | -66.74% |
| 2017 FY | - CNY | -19.12% |
| 2017 Q1 | 16.39 Million CNY | -53.33% |
| 2017 Q2 | 24.63 Million CNY | 50.29% |
| 2016 FY | - CNY | 23.53% |
| 2016 Q4 | 35.12 Million CNY | 273.52% |
| 2016 Q3 | 9.4 Million CNY | -70.11% |
| 2016 Q2 | 31.46 Million CNY | 341.32% |
| 2016 Q1 | 7.12 Million CNY | -21.36% |
| 2015 Q4 | 9.06 Million CNY | -45.77% |
| 2015 FY | - CNY | -1.51% |
| 2015 Q1 | 15.28 Million CNY | -32.39% |
| 2015 Q2 | 19.72 Million CNY | 29.08% |
| 2015 Q3 | 16.71 Million CNY | -15.26% |
| 2014 Q3 | 19.25 Million CNY | -3.5% |
| 2014 FY | - CNY | 34.92% |
| 2014 Q1 | 13.69 Million CNY | -47.55% |
| 2014 Q2 | 19.95 Million CNY | 45.72% |
| 2014 Q4 | 22.6 Million CNY | 17.37% |
| 2013 Q4 | 26.11 Million CNY | 191.15% |
| 2013 FY | - CNY | 9.94% |
| 2013 Q1 | 6.23 Million CNY | -76.39% |
| 2013 Q2 | 17.45 Million CNY | 179.74% |
| 2013 Q3 | 8.96 Million CNY | -48.62% |
| 2012 Q4 | 26.43 Million CNY | 293.83% |
| 2012 FY | - CNY | 13.72% |
| 2012 Q2 | 11.22 Million CNY | 103.25% |
| 2012 Q3 | 6.71 Million CNY | -40.19% |
| 2012 Q1 | 5.52 Million CNY | 6.65% |
| 2011 Q2 | 19.14 Million CNY | 47.0% |
| 2011 Q1 | 13.02 Million CNY | -54.89% |
| 2011 FY | - CNY | -15.61% |
| 2011 Q4 | 5.17 Million CNY | -57.09% |
| 2011 Q3 | 12.06 Million CNY | -36.98% |
| 2010 Q4 | 28.86 Million CNY | 280.24% |
| 2010 Q3 | 7.59 Million CNY | 0.0% |
| 2010 FY | - CNY | 34.96% |
| 2009 FY | - CNY | 62.32% |
| 2008 FY | - CNY | 69.14% |
| 2007 FY | - CNY | 0.0% |